Richard Carvajal on Immunotherapy Dosing

The FDA has approved adjuvant nivolumab to treat completely resected stage IIB/C melanoma.

Amber Pierce RN, BSN, OCN, highlights the importance of a 2-step verification process with fixed-dose regimen therapies.

ASCO has updated its recommendations for systemic therapies in melanoma.

Krista M. Rubin, RN, MS, FNP-BC, highlights how nurses can help patients with uveal melanoma anticipate and manage adverse events during the step-up dosing period with tebentafusp.

Patients about to undergo Mohs microscopic surgery reported that they were more likely to request over-the-counter medications if they perceived their risk of opioid addiction to be high.

The FDA has launched a priority review of lifileucel based on data from the phase 2 C-144-01 trial.